Literature DB >> 9120323

The epidemiology of community-acquired pneumonia among hospitalized adults.

A Porath1, F Schlaeffer, D Lieberman.   

Abstract

OBJECTIVE: To identify and characterize the aetiological agents of community-acquired pneumonia (CAP) among hospitalized patients, as an aid in therapeutic decision-making.
METHOD: A prospective 1 year study of all patients hospitalized with CAP in the Negev region of Israel. The aetiology was determined by blood and pleural fluid cultures, and specific serological testing for pathogenic agents. Eighty-nine percent of the patients underwent follow-up for a month after discharge.
RESULTS: The study included 346 patients (53% males, mean age 49.3 +/- 19.5, range 17-94). A single aetiologic agent was identified in 146 patients (42.2%), multiple agents were found in 133 (38.4%), and no agent was identified in 67 (19.4%). Among the common pathogens were Pneumococcus sp. in 148 patients (42.8%). Mycoplasma pneumoniae (101, 29.2%), Chlamydia pneumoniae (62, 17.9%), Legionella sp. (56, 16.2%), viruses (35, 10.1%), Coxiella burnetti (20, 5.8%). Haemophilus influenzae (19, 5.5%), and other bacteria (21, 6.1%). Approximately 70% of the patients infected with M. pneumoniae and C. burnetti were younger than 45 years (P < 0.05). In contrast, about 50% of the patients with C. pneumoniae (TWAR) were over the age of 65 (P = 0.03). The presence of comorbidity was associated with a greater frequency of bacterial aetiologies (57% vs. 44%, P = 0.02), and fewer infections with M. pneumoniae (15% vs. 36%, P = 0.0004), or C. burnetii (2% vs. 8%, P = 0.02). Specific causative agents were associated with specific seasons: viruses between December and April (P = 0.03), and Legionella sp. from July to October (P = 0.003). In contrast, no seasonal variation was associated with pneumococcus, M. pneumoniae, or C. pneumoniae (TWAR).
CONCLUSIONS: Patients are hospitalized with CAP throughout the year. Since the pathogen is usually unknown at hospitalization, epidemiological data is important for choosing medication. The findings of this study point to the importance of macrolides alone or in combination with cephalosporins, as the treatment of choice for patients in our region.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9120323     DOI: 10.1016/s0163-4453(97)80008-4

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  17 in total

1.  Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens.

Authors:  G Hoeffken; D Talan; L S Larsen; S Peloquin; S H Choudhri; D Haverstock; P Jackson; D Church
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10       Impact factor: 3.267

2.  Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society.

Authors:  L A Mandell; T J Marrie; R F Grossman; A W Chow; R H Hyland
Journal:  Can J Infect Dis       Date:  2000-09

Review 3.  Community-acquired pneumonia.

Authors:  Mark Loeb
Journal:  BMJ Clin Evid       Date:  2010-08-18

Review 4.  Activity of quinolones against Chlamydia pneumoniae.

Authors:  M R Hammerschlag
Journal:  Drugs       Date:  1999       Impact factor: 9.546

5.  Chlamydia pneumoniae and Mycoplasma pneumoniae pneumonia: comparison of clinical, epidemiological characteristics and laboratory profiles.

Authors:  I Puljiz; I Kuzman; O Dakovic-Rode; N Schönwald; B Mise
Journal:  Epidemiol Infect       Date:  2005-11-29       Impact factor: 2.451

Review 6.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Hyperoside inhibits proinflammatory cytokines in human lung epithelial cells infected with Mycoplasma pneumoniae.

Authors:  Fang Liu; YuHua Zhao; JieMin Lu; ShuangHui Chen; XinGuang Zhang; WenWei Mao
Journal:  Mol Cell Biochem       Date:  2018-10-22       Impact factor: 3.396

Review 8.  Community-acquired pneumonia.

Authors:  Mark Loeb
Journal:  BMJ Clin Evid       Date:  2008-07-17

9.  [Update to the Latin American Thoracic Association (ALAT) recommendations on community acquired pneumonia].

Authors: 
Journal:  Arch Bronconeumol       Date:  2004-08       Impact factor: 4.872

10.  Community-acquired pneumonia: pneumococcal vaccine.

Authors:  Mark Loeb
Journal:  BMJ Clin Evid       Date:  2015-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.